Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.

Meperidine as the Single Sedative Agent for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01948921

Enrollment

110

Registered

2013-09-24

Start date

2013-09-30

Completion date

2017-03-31

Last updated

2017-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients Undergoing Diagnostic EGD

Keywords

EGD, tolerance, discomfort

Brief summary

Our pilot results showed that meperidine reduce patient discomfort during EGD (esophagogastroduodenoscopy). But many patients can tolerate EGD well without any sedative agents. So the investigators target the use of meperidine on patients expected to have poor tolerance in this study, which includ young females with high anxiety level and patients with prior poor tolerance. The investigators test the hypothesis that meperidine improves tolerance and alleviates discomfort for patients expected to have poor tolerance during diagnostic EGD.

Interventions

DRUGplacebo

DRUGMeperidine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* female youger than 65 years with high anxiety level * patients with previous poor tolerance of EGD

Exclusion criteria

* a therapeutic EGD * sedation with other agents * contraindication to Buscopan (hyoscine N-butylbromide) or meperidine * American Society of Anesthesiology (ASA) risk Class 3 or higher, renal failure * age less than 20 years or more than 80 years * pregnancy * refusal to provide written informed consent. All participants signed written informed consents

Design outcomes

Primary

Measure	Time frame	Description
discomfort score during esophageal intubation	10 minutes	self-reported discomfort score during esophageal intubation, assessed with a 0 to 10 (0 = none; 10 = unbearable) visual analog scale (VAS).

Secondary

Measure	Time frame
patient discomfort score during the procedure	10 minutes
patients satisfaction score	10 minutes
patient tolerance score evaluated by the endoscopist	10 minutes
endoscopist satisfaction score	10 minutes

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026